Geron Bolsters Board with Biopharma Veterans to Drive RYTELO Growth
Event summary
- Geron Corporation added Patricia S. Andrews and Constantine Chinoporos to its Board of Directors on March 26, 2026.
- Andrews brings extensive commercial-stage biopharma experience, including CEO roles at Sumitomo Pharma Oncology and leadership positions at Incyte and Pfizer.
- Chinoporos has a background in business development and operations, with experience at Applied Therapeutics, Albireo Pharmaceuticals, and Sanofi.
- Both new directors emphasize Geron's focus on commercializing RYTELO for lower-risk myelodysplastic syndromes (LR-MDS).
- Geron is also conducting a pivotal Phase 3 trial for imetelstat in JAK-inhibitor relapsed/refractory myelofibrosis.
The big picture
Geron's board refresh signals a push for operational discipline as it seeks to establish RYTELO as a cornerstone therapy in LR-MDS. The appointments come amid heightened competition in hematology, where commercial execution and regulatory agility will determine long-term differentiation. With both directors boasting commercial-stage experience, Geron appears to be prioritizing near-term revenue growth over exploratory science.
What we're watching
- Commercial Execution
- How Geron leverages Andrews' and Chinoporos' expertise to accelerate RYTELO adoption in LR-MDS.
- Strategic Focus
- Whether the new directors can help Geron sustain its pivot toward hematology leadership.
- Clinical Pipeline
- The pace at which Geron advances imetelstat through Phase 3 trials in myelofibrosis.
Related topics